98 related articles for article (PubMed ID: 9869197)
1. Potential of autologous immunologic effector cells for prediction of progression of disease in patients with chronic myelogenous leukemia.
Müller M; Scheffold C; Lefterova P; Huhn D; Neubauer A; Schmidt-Wolf IG
Leuk Lymphoma; 1998 Oct; 31(3-4):335-41. PubMed ID: 9869197
[TBL] [Abstract][Full Text] [Related]
2. Potential of autologous immunologic effector cells for bone marrow purging in patients with chronic myeloid leukemia.
Scheffold C; Brandt K; Johnston V; Lefterova P; Degen B; Schöntube M; Huhn D; Neubauer A; Schmidt-Wolf IG
Bone Marrow Transplant; 1995 Jan; 15(1):33-9. PubMed ID: 7538001
[TBL] [Abstract][Full Text] [Related]
3. Cytokine treatment of human bone marrow activates anti-leukaemia effector cells: monitoring of purging by polymerase chain reaction and DNA analysis.
Dickinson AM; Middleton SL; Latham J; Dunn J; Thomas L; Proctor SJ
Leukemia; 1995 Mar; 9(3):444-9. PubMed ID: 7533866
[TBL] [Abstract][Full Text] [Related]
4. Expansion and activation of human natural killer cells as therapy for autologous transplantation.
Miller JS; Verfaillie C; McGlave P
Prog Clin Biol Res; 1994; 389():39-45. PubMed ID: 7700914
[No Abstract] [Full Text] [Related]
5. BCR-ABL does not prevent apoptotic death induced by human natural killer or lymphokine-activated killer cells.
Roger R; Issaad C; Pallardy M; Léglise MC; Turhan AG; Bertoglio J; Bréard J
Blood; 1996 Feb; 87(3):1113-22. PubMed ID: 8562937
[TBL] [Abstract][Full Text] [Related]
6. Significance of cytogenetic and fluorescence in situ hybridization analysis in evaluating antichronic myeloid leukemia efficacy of different immune effector cells.
Tong CR; Hong B; Qiu JY; Chen Z; Lu DP
Cancer Genet Cytogenet; 2002 Apr; 134(1):21-4. PubMed ID: 11996791
[TBL] [Abstract][Full Text] [Related]
7. [Autologous bone marrow transplantation for patients with chronic myelogenous leukemia after in vitro purging of the graft with bcr/abl antisense oligodeoxynucleotides].
Sun J; Wu B; Liu Q; Feng R; Liu X; Meng F; Zhou S
Zhonghua Xue Ye Xue Za Zhi; 2000 Aug; 21(8):400-2. PubMed ID: 11877009
[TBL] [Abstract][Full Text] [Related]
8. Ex vivo purging with NK-92 prior to autografting for chronic myelogenous leukemia.
Maki G; Tam YK; Berkahn L; Klingemann HG
Bone Marrow Transplant; 2003 Jun; 31(12):1119-25. PubMed ID: 12796791
[TBL] [Abstract][Full Text] [Related]
9. Usefulness of lymphokine-activated killer cells generated from bone marrow mononuclear cells for the purging of residual tumor cells in peripheral blood stem cell graft.
Komatsu F; Kajiwara M
Jpn J Cancer Res; 1996 Feb; 87(2):161-9. PubMed ID: 8609065
[TBL] [Abstract][Full Text] [Related]
10. Purging efficacy of ZnPcH₁-based photodynamic therapy on chronic myeloid leukemia bone marrow.
Huang H; Chen Y; Chen W; Wu Y
Int J Lab Hematol; 2011 Oct; 33(5):477-82. PubMed ID: 21457188
[TBL] [Abstract][Full Text] [Related]
11. Generation of activated natural killer (A-NK) cells in patients with chronic myelogenous leukaemia and their role in the in vitro disappearance of BCR/abl-positive targets.
Silla LM; Pincus SM; Locker JD; Glover J; Elder EM; Donnenberg AD; Nardi NB; Bryant J; Ball ED; Whiteside TL
Br J Haematol; 1996 May; 93(2):375-85. PubMed ID: 8639431
[TBL] [Abstract][Full Text] [Related]
12. Relative roles of natural killer- and T cell-mediated anti-leukemia effects in chronic myelogenous leukemia patients treated with interferon-alpha.
Pawelec G; Da Silva P; Max H; Kalbacher H; Schmidt H; Bruserud O; Zügel U; Baier W; Rehbein A; Pohla H
Leuk Lymphoma; 1995 Aug; 18(5-6):471-8. PubMed ID: 8528055
[TBL] [Abstract][Full Text] [Related]
13. [Specific anti-leukemic cell effect mediated by dendritic cells pulsed with chronic myelogenous leukemia lysate antigen in vitro].
Zhu HH; Xu KL; Pan XY; Liu JQ; Chen FX; Huang YH
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2003 Jun; 11(3):278-81. PubMed ID: 12844413
[TBL] [Abstract][Full Text] [Related]
14. Adherent lymphokine-activated killer cells in chronic myelogenous leukemia: a benign cell population with potent cytotoxic activity.
Verfaillie C; Miller W; Kay N; McGlave P
Blood; 1989 Aug; 74(2):793-7. PubMed ID: 2473805
[TBL] [Abstract][Full Text] [Related]
15. [The effect of anti-bcr-abl hammerhead ribozyme on bone marrow purging].
Wu Y; Chen YZ; Huang HF; Chen P; Lu LH
Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai); 2003 Sep; 35(9):859-63. PubMed ID: 12958661
[TBL] [Abstract][Full Text] [Related]
16. A phase I/II clinical trial of autologous cytokine-induced killer cells as adjuvant immunotherapy for acute and chronic myeloid leukemia in clinical remission.
Linn YC; Yong HX; Niam M; Lim TJ; Chu S; Choong A; Chuah C; Goh YT; Hwang W; Loh Y; Ng HJ; Suck G; Chan M; Koh M
Cytotherapy; 2012 Aug; 14(7):851-9. PubMed ID: 22799277
[TBL] [Abstract][Full Text] [Related]
17. Effects of BCR-ABL antisense oligonucleotides (AS-ODN) on human chronic myeloid leukemic cells: AS-ODN as effective purging agents.
Wu AG; Joshi SS; Chan WC; Iversen PL; Jackson JD; Kessinger A; Pirruccello SJ; Sanger WG; Sharp JG; Verbik DJ
Leuk Lymphoma; 1995 Dec; 20(1-2):67-76. PubMed ID: 8750625
[TBL] [Abstract][Full Text] [Related]
18. Preferential sequestration in vitro of BCR/ABL negative hematopoietic progenitor cells among cytokine nonresponsive CML marrow CD34+ cells.
Veena P; Cornetta K; Davidson A; Agüero B; McMahel J; Traycoff CM; Srour EF
Bone Marrow Transplant; 1997 Jun; 19(12):1213-21. PubMed ID: 9208115
[TBL] [Abstract][Full Text] [Related]
19. BCR/ABL promotes dendritic cell-mediated natural killer cell activation.
Terme M; Borg C; Guilhot F; Masurier C; Flament C; Wagner EF; Caillat-Zucman S; Bernheim A; Turhan AG; Caignard A; Zitvogel L
Cancer Res; 2005 Jul; 65(14):6409-17. PubMed ID: 16024645
[TBL] [Abstract][Full Text] [Related]
20. [An experimental study on bone marrow purging in vitro for patients with chronic myelogenous leukemia].
Liu J; Jiang J; Zhang Y; Wu D; Yang G; Huang X; Wei X
Hua Xi Yi Ke Da Xue Xue Bao; 2001 Dec; 32(4):599-601. PubMed ID: 12528561
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
